icon-folder.gif   Conference Reports for NATAP  
 
  ID Week
Oct 21 - October 25
Back grey_arrow_rt.gif
 
 
 
SUMMARY OF COVID-RELATED IMPACT ON
CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING (CAB + RPV LA) DOSING ACROSS THE SIX ONGOING
GLOBAL PHASE IIB and III CLINICAL TRIALS

 
 
  IDWeek 2020 Oct 21-25 virtual
Reported by Jules Levin
 
Maggie Czarnogorski, MD, MPH1; Ronald D'Amico, DO, MSc1; Paul Benn, MB ChB, FRCP2; Cindy McCoig, MD3; Sandy Griffith, PharmD1; Kris Hudson, PhD1; Ken Sutton, MS1; Conn Harrington, BA1; Sterling Wu, PhD4; Will Williams, BS4; Kai Hove, MRes5; Carlos Martín Espanol, MSc5; Jane Fricker, BS5; Parul Patel, PharmD1; David Margolis, MD1
 
1ViiV Healthcare, Research Triangle Park, NC, USA; 2ViiV Healthcare, Brentford, UK; 3ViiV Healthcare, Madrid, Spain;
4GlaxoSmithKline, Collegeville, PA, USA; 5GlaxoSmithKline, London, UK

1028201

1028202

1028203

1028204